Also, keep in mind that Gilead has a trial underway for their BET inhibitor GS-5829 for metastatic castrate-resistant prostate cancer (mCRPC) that is also investigating synergy with enzalutamide. The Gilead study is listed as having a study start date of December 2015, whereas the Zenith ZEN-3694 trial is listed as starting in April 2016. Zenith didn't start dosing until June 15, 2016. This Gilead trial is the only other BET inhibitor trial focused on mCRPC other than Zenith. It will be interesting to follow this development.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

https://clinicaltrials.gov/ct2/show/NCT02607228